John C. Reed
CIK: 0001181561
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (25 total)
- Aug 15, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Award(A)Direct647 shares- - May 1, 2026JNJ
JOHNSON & JOHNSON
Tax Payment(F)Direct11K shares at avg. $229.85$2.5M - May 1, 2026JNJ
JOHNSON & JOHNSON
Exercise(M)Direct25.3K shares- - Feb 17, 2026JNJ
JOHNSON & JOHNSON
Sale(S)Direct2.3K shares at avg. $243.00$555K - Feb 17, 2026JNJ
JOHNSON & JOHNSON
Exercise(M)Direct21.7K shares at avg. $157.92$3.4M - Feb 17, 2026JNJ
JOHNSON & JOHNSON
Sale(S)Direct21.7K shares at avg. $243.00$5.3M - Feb 17, 2026JNJ
JOHNSON & JOHNSON
Exercise(M)Direct29.9K shares at avg. $156.15$4.7M - Feb 17, 2026JNJ
JOHNSON & JOHNSON
Sale(S)Direct29.9K shares at avg. $243.00$7.3M - Feb 15, 2026JNJ
JOHNSON & JOHNSON
Tax Payment(F)Direct528 shares at avg. $243.45$129K - Feb 15, 2026JNJ
JOHNSON & JOHNSON
Award(A)DirectRestricted Share Units
3.5K shares- - Feb 15, 2026JNJ
JOHNSON & JOHNSON
Award(A)DirectEmployee Stock Options (Right to Buy)
49.4K shares- - Feb 15, 2026JNJ
JOHNSON & JOHNSON
Exercise(M)Direct1.8K shares- - Feb 15, 2026JNJ
JOHNSON & JOHNSON
Exercise(M)Direct1.3K shares- - Feb 15, 2026JNJ
JOHNSON & JOHNSON
Tax Payment(F)Direct385 shares at avg. $243.45$94K - Oct 17, 2025JNJ
JOHNSON & JOHNSON
Exercise(M)Direct21.7K shares at avg. $157.92$3.4M - Oct 17, 2025JNJ
JOHNSON & JOHNSON
Sale(S)Direct21.7K shares at avg. $192.71$4.2M - Jul 17, 2025JNJ
JOHNSON & JOHNSON
Sale(S)Direct19.1K shares at avg. $163.55$3.1M - May 1, 2025JNJ
JOHNSON & JOHNSON
Exercise(M)Direct25.3K shares- - May 1, 2025JNJ
JOHNSON & JOHNSON
Tax Payment(F)Direct11K shares at avg. $156.31$1.7M - Feb 18, 2025JNJ
JOHNSON & JOHNSON
Tax Payment(F)Direct385 shares at avg. $156.15$60K - Feb 15, 2025JNJ
JOHNSON & JOHNSON
Award(A)DirectEmployee Stock Options (Right to Buy)
89.8K shares- - Feb 15, 2025JNJ
JOHNSON & JOHNSON
Award(A)DirectRestricted Share Units
5.5K shares- - Feb 15, 2025JNJ
JOHNSON & JOHNSON
Exercise(M)Direct1.4K shares- - May 1, 2024JNJ
JOHNSON & JOHNSON
Exercise(M)Direct25.3K shares- - May 1, 2024JNJ
JOHNSON & JOHNSON
Tax Payment(F)Direct11K shares at avg. $144.59$1.6M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 15, 2026 |  MDGL MADRIGAL PHARMACEUTICALS, INC. | Award(A) | 647 | - | $0 | Direct |
| May 1, 2026 |  JNJ JOHNSON & JOHNSON | Tax Payment(F) | 11,002 | $229.85 | $2,528,810 | Direct |
| May 1, 2026 | JNJ JOHNSON & JOHNSON | Exercise(M) | 25,255 | - | $0 | Direct |
| Feb 17, 2026 | JNJ JOHNSON & JOHNSON | Sale(S) | 2,283 | $243.00 | $554,769 | Direct |
| Feb 17, 2026 | JNJ JOHNSON & JOHNSON | Exercise(M) | 21,721 | $157.92 | $3,430,180 | Direct |
| Feb 17, 2026 | JNJ JOHNSON & JOHNSON | Sale(S) | 21,721 | $243.00 | $5,278,203 | Direct |
| Feb 17, 2026 | JNJ JOHNSON & JOHNSON | Exercise(M) | 29,927 | $156.15 | $4,673,101 | Direct |
| Feb 17, 2026 | JNJ JOHNSON & JOHNSON | Sale(S) | 29,927 | $243.00 | $7,272,261 | Direct |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | Tax Payment(F) | 528 | $243.45 | $128,542 | Direct |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | Award(A) Restricted Share Units | 3,546 | - | - | Direct |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | Award(A) Employee Stock Options (Right to Buy) | 49,382 | - | - | Direct |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | Exercise(M) | 1,847 | - | $0 | Direct |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | Exercise(M) | 1,349 | - | $0 | Direct |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | Tax Payment(F) | 385 | $243.45 | $93,728 | Direct |
| Oct 17, 2025 | JNJ JOHNSON & JOHNSON | Exercise(M) | 21,721 | $157.92 | $3,430,180 | Direct |
| Oct 17, 2025 | JNJ JOHNSON & JOHNSON | Sale(S) | 21,721 | $192.71 | $4,185,793 | Direct |
| Jul 17, 2025 | JNJ JOHNSON & JOHNSON | Sale(S) | 19,137 | $163.55 | $3,129,830 | Direct |
| May 1, 2025 | JNJ JOHNSON & JOHNSON | Exercise(M) | 25,255 | - | - | Direct |
| May 1, 2025 | JNJ JOHNSON & JOHNSON | Tax Payment(F) | 11,002 | $156.31 | $1,719,723 | Direct |
| Feb 18, 2025 | JNJ JOHNSON & JOHNSON | Tax Payment(F) | 385 | $156.15 | $60,118 | Direct |
| Feb 15, 2025 | JNJ JOHNSON & JOHNSON | Award(A) Employee Stock Options (Right to Buy) | 89,781 | - | - | Direct |
| Feb 15, 2025 | JNJ JOHNSON & JOHNSON | Award(A) Restricted Share Units | 5,539 | - | - | Direct |
| Feb 15, 2025 | JNJ JOHNSON & JOHNSON | Exercise(M) | 1,350 | - | - | Direct |
| May 1, 2024 | JNJ JOHNSON & JOHNSON | Exercise(M) | 25,255 | - | $0 | Direct |
| May 1, 2024 | JNJ JOHNSON & JOHNSON | Tax Payment(F) | 10,984 | $144.59 | $1,588,177 | Direct |
1-25 of 25 transactions
About REED JOHN C
REED JOHN C (SEC CIK 0001181561) files insider reports with the SEC as Director of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and EVP, Innovative Medicine, R&D of JOHNSON & JOHNSON (JNJ).
Signal8 holds 10 ownership filings by REED JOHN C (1 Form 3, 9 Form 4), filed between Oct 31, 2024 and Aug 18, 2026. Those filings report 25 transactions, from May 1, 2024 to Aug 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on REED JOHN C's filings is in WEST CONSHOHOCKEN, PA.
Recent filings by REED JOHN C
- Aug 15, 2026: Grant or award of MDGL shares (Form 4, code A).
- May 1, 2026: Tax withholding of JNJ shares (Form 4, code F).
- May 1, 2026: Option exercise of JNJ shares (Form 4, code M).
- Feb 17, 2026: Open-market sale of JNJ shares (Form 4, code S).
- Feb 17, 2026: Option exercise of JNJ shares (Form 4, code M).
Other insiders filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Sibold William John, President and CEO
- Kelley Shannon T, General Counsel
- Taub Rebecca, Director
- Levy Richard S, Director
- FOUSE JACQUALYN A, Director
- Daly James M, Director